Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer

Title: Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer
Authors: Kınıkoğlu, Oğuzcan; Altıntaş, Yunus Emre; Yıldız, Anıl; Akdağ, Goncagül; Bal, Hamit; Yaşar, Zeynep Yüksel; Özkerim, Uğur; Yıldız, Hacer Şahika; Öksüz, Sıla; Tünbekici, Salih; Doğan, Akif; Işık, Deniz; Yaşar, Alper; Başoğlu, Tuğba; Sürmeli, Heves; Odabaş, Hatice; Turan, Nedim
Source: The Oncologist ; volume 30, issue 4 ; ISSN 1083-7159 1549-490X
Publisher Information: Oxford University Press (OUP)
Publication Year: 2025
Description: Background Tumor-infiltrating lymphocytes (TILs) have emerged as predictive biomarkers in HER2-positive breast cancer, correlating with treatment response and survival outcomes. This study evaluates the impact of TIL levels and Ki67 suppression on neoadjuvant therapy efficacy in this patient population. Materials and methods A retrospective analysis of 136 HER2-positive breast cancer patients was conducted. Patients were stratified by TIL levels, and clinical outcomes, including Ki67 expression, pathological complete response (pCR), and disease-free survival (DFS), were assessed. Results High TIL levels (≥ 40%) were significantly associated with higher pCR rates (60.32% vs. 39.73%, P = .02) and with TIL ≥ 10% greater Ki67 suppression. In patients with low TIL levels, high Ki67 expression correlated with better pCR rates (57.1% vs 30.8%, P = 0.010), while in high TIL patients, no significant difference was observed between high and low Ki67 groups (P = 0.317). A trend toward improved DFS was noted in the high TIL group, with 3-year survival rates of 91.9% vs. 80.7% in the low TIL group, though this was not statistically significant (P = .062). Conclusion TIL levels are robust predictors of pCR and Ki67 suppression in HER2-positive breast cancer, particularly in patients with high initial TILs. These findings highlight the potential for integrating TIL evaluation into personalized treatment strategies to optimize neoadjuvant therapy outcomes. Further research is warranted to validate these results and explore underlying mechanisms.
Document Type: article in journal/newspaper
Language: English
DOI: 10.1093/oncolo/oyaf054
Availability: https://doi.org/10.1093/oncolo/oyaf054; https://academic.oup.com/oncolo/article-pdf/30/4/oyaf054/62996691/oyaf054.pdf
Rights: https://creativecommons.org/licenses/by/4.0/
Accession Number: edsbas.D2C8D0C2
Database: BASE